Identification of the first surrogate agonists for the G protein-coupled receptor GPR132

We report the first pharmacological tool agonist for in vitro characterization of the orphan receptor GPR132, preliminary structure–activity relationships based on 32 analogs and a suggested binding mode from docking.M.A.S. was supported by a research scholarship from the Drug Research Academy and Novo Nordisk A/S. D.E.G. and H.B.-O. gratefully acknowledge financial support by the Carlsberg Foundation. D.E.G. and D.S.P. gratefully acknowledges financial support by the Lundbeck Foundation. Nils Nyberg is acknowledged for help with NMR spectroscopy. NMR equipment used in this work was purchased via a grant from The Lundbeck Foundation (R77-A6742).This is the accepted manuscript. The final version is available at http://pubs.rsc.org/en/Content/ArticleLanding/2015/RA/c5ra04804d#!divAbstract

Synthesis of 2'-amino-LNA: A new strategy

In this paper we present revised and significantly improved synthetic routes to 2’-amino-LNA (locked nucleic acid). The optimal route is convergent with the synthesis of LNA monomers (“2’-oxy-LNA”)via a common intermediate obtained by a mild deacetylation for the liberation of the 2’-hydroxy group to give compound 23 without the concomitant ring closure that affords the 2’-oxy-LNA skeleton. After inversion of the stereochemistry at C2’ and triflate formation at the 2’-hydroxy group a new common intermediate 16 is obtained which gives easy access to a range of other analogues exemplified by the introduction of a sulfur nucleophile leading to the 2’-thio-LNA structure. After substitution of the triflate with azide a basic reduction affords the desired 2’-amino-LNA structure, i.e., compound 18. This new synthesis strategy towards 2’-amino-LNA improves the overall yield significantly and converges the syntheses of 2’-oxy-LNA and LNA analogues

Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors

Peptide-derived protease inhibitors are an important class of compounds with the potential to treat a wide range of diseases. Herein, we describe the synthesis of a series of triazole-containing macrocyclic protease inhibitors pre-organized into a β-strand conformation and an evaluation of their activity against a panel of proteases. Acyclic azido–alkyne-based aldehydes are also evaluated for comparison. The macrocyclic peptidomimetics showed considerable activity towards calpain II, cathepsin L and S, and the 20S proteasome chymotrypsin-like activity. Some of the first examples of highly potent macrocyclic inhibitors of cathepsin S were identified. These adopt a well-defined β-strand geometry as shown by NMR spectroscopy, X-ray analysis, and molecular docking studies

Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors

Peptide-derived protease inhibitors are an important class of compounds with the potential to treat a wide range of diseases. Herein, we describe the synthesis of a series of triazole- containing macrocyclic protease inhibitors pre-organized into a b-strand conformation and an evaluation of their activity against a panel of proteases. Acyclic azidoalkyne-based aldehydes are also evaluated for comparison. The macrocyclic peptidomimetics showed considerable activity towards calpain II, cathepsin L and S, and the 20S proteasome chymotrypsin-like activity. Some of the first examples of highly potent macrocyclic inhibitors of cathepsin S were identified. These adopt a well-defined b-strand geometry as shown by NMR spectroscopy, X-ray analysis, and molecular docking studies. © 2013 Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim.Associated Grant:Australian Research Counci

Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor

The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low and many patients experiencing an initial response eventually relapse. Thus, the need for more efficacious treatments remains. Previous studies have reported that mixtures of antibodies targeting multiple distinct epitopes are more effective than single mAbs at inhibiting growth of human cancer cells in vitro and in vivo. The current work describes the rational approach that led to discovery and selection of a novel anti-EGFR antibody mixture Sym004, which is currently in Phase 2 clinical testing. Twenty-four selected anti-EGFR antibodies were systematically tested in dual and triple mixtures for their ability to inhibit cancer cells in vitro and tumor growth in vivo. The results show that targeting EGFR dependent cancer cells with mixtures of antibodies is superior at inhibiting their growth both in vitro and in vivo. In particular, antibody mixtures targeting non-overlapping epitopes on domain III are efficient and indeed Sym004 is composed of two monoclonal antibodies targeting this domain. The superior growth inhibitory activity of mixtures correlated with their ability to induce efficient EGFR degradation

Quantitative analysis of geraniol, nerol, linalool, and a-terpineol in wine

A mixture of [²H₇]-geraniol, [²H₇]-nerol, [²H₇]-linalool and [²H₇]-f-terpineol was prepared for use as internal standards in a rapid and accurate analytical method, employing gas chromatography-mass spectrometry (GC/MS), to determine the concentration of geraniol, nerol, linalool and f-terpineol in wine. The method avoids the possible formation, degradation and interconversion of these compounds during their analysis

Selective inhibition of biotin protein ligase from Staphylococcus aureus

There is a well documented need to replenish the antibiotic pipeline with new agents to combat the rise of drug resistant bacteria. One strategy to combat resistance is to discover new chemical classes immune to current resistance mechanisms that inhibit essential metabolic enzymes. Many of the obvious drug targets that have no homologous isozyme in the human host have now been investigated. Bacterial drug targets that have a closely related human homologue represent a new frontier in antibiotic discovery. However, to avoid potential toxicity to the host, these inhibitors must have very high selectivity for the bacterial enzyme over the human homolog. We have demonstrated that the essential enzyme biotin protein ligase (BPL) from the clinically important pathogen Staphylococcus aureus could be selectively inhibited. Linking biotin to adenosine via a 1,2,3 triazole yielded the first BPL inhibitor selective for S. aureus BPL over the human equivalent. The synthesis of new biotin 1,2,3-triazole analogues using click chemistry yielded our most potent structure (Ki 90 nM) with a >1100-fold selectivity for the S. aureus BPL over the human homologue. X-ray crystallography confirmed the mechanism of inhibitor binding. Importantly, the inhibitor showed cytotoxicity against S. aureus but not cultured mammalian cells. The biotin 1,2,3-triazole provides a novel pharmacophore for future medicinal chemistry programs to develop this new antibiotic class.Tatiana P. Soares da Costa, William Tieu, Min Y. Yap, Nicole R. Pendini, Steven W. Polyak, Daniel Sejer Pedersen, Renato Morona, John D. Turnidge, John C. Wallace, Matthew C.J. Wilce, Grant W. Booker and Andrew D. Abel